Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report) is one of 1,060 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its competitors? We will compare Cartesian Therapeutics to similar companies based on the strength of its valuation, institutional ownership, dividends, analyst recommendations, risk, profitability and earnings.
Insider & Institutional Ownership
86.9% of Cartesian Therapeutics shares are owned by institutional investors. Comparatively, 44.1% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 57.9% of Cartesian Therapeutics shares are owned by insiders. Comparatively, 13.7% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Cartesian Therapeutics and its competitors gross revenue, earnings per share and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
Cartesian Therapeutics | $47.94 million | -$219.71 million | -0.32 |
Cartesian Therapeutics Competitors | $9.58 billion | $147.90 million | -5.54 |
Risk & Volatility
Cartesian Therapeutics has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500. Comparatively, Cartesian Therapeutics’ competitors have a beta of 3.70, suggesting that their average stock price is 270% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of current ratings and price targets for Cartesian Therapeutics and its competitors, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Cartesian Therapeutics | 0 | 2 | 8 | 0 | 2.80 |
Cartesian Therapeutics Competitors | 7837 | 21295 | 48948 | 1244 | 2.55 |
Cartesian Therapeutics presently has a consensus price target of $42.86, suggesting a potential upside of 154.35%. As a group, “Pharmaceutical preparations” companies have a potential upside of 186.07%. Given Cartesian Therapeutics’ competitors higher possible upside, analysts clearly believe Cartesian Therapeutics has less favorable growth aspects than its competitors.
Profitability
This table compares Cartesian Therapeutics and its competitors’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Cartesian Therapeutics | -510.72% | N/A | -6.03% |
Cartesian Therapeutics Competitors | -3,590.11% | -276.96% | -39.10% |
Summary
Cartesian Therapeutics beats its competitors on 8 of the 13 factors compared.
About Cartesian Therapeutics
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.
Receive News & Ratings for Cartesian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cartesian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.